Marianne C. Verhaar

Modulation of TGF-β/BMP-6 expression and increased levels of circulating smooth muscle progenitor cells in a type I diabetes mouse model.

Bone-marrow-derived cells contribute to endothelial repair after thrombotic microangiopathy.

Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis.

Endothelial progenitor cells: mainly derived from the monocyte/macrophage-containing CD34- mononuclear cell population and only in part from the hematopoietic stem cell-containing CD34+ mononuclear cell population.

Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes.

Presence of the metabolic syndrome does not impair coronary collateral vessel formation in patients with documented coronary artery disease.

CD34+ cells home, proliferate, and participate in capillary formation, and in combination with CD34- cells enhance tube formation in a 3-dimensional matrix.

Prognostic significance of coronary collaterals in patients with coronary heart disease having percutaneous transluminal coronary angioplasty.

Cardiac ischemic score determines the presence of coronary collateral circulation.

A study of neovascularization in the rat ischemic hindlimb using Araldite casting and Spalteholtz tissue clearing.

Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase.

Role of circulating karyocytes in the initiation and progression of atherosclerosis.

Coronary collateral circulation: the effects of smoking and alcohol.

Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors.

Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome.

End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells.

Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus.

Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus.

Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo.

Understanding eNOS for pharmacological modulation of endothelial function: a translational view.

Technology insight: Innovative options for end-stage renal disease--from kidney refurbishment to artificial kidney.

Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing.

Angiogenic sprouting from the aortic vascular wall is impaired in the BB rat model of autoimmune diabetes.

Progenitor cell therapy in patients with critical limb ischemia without surgical options.

RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy.

Circulating endothelial progenitor cell levels are higher during childhood than in adult life.

Insights into mechanisms behind arteriogenesis: what does the future hold?

Directing myogenic mesenchymal stem cell differentiation.

Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy.

Comment on: Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells.

The use of endothelial progenitor cells for prevascularized bone tissue engineering.

Protective Actions of PPAR-gamma Activation in Renal Endothelium.

TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro.

Endothelial progenitor cell dysfunction in rheumatic disease.

Smooth muscle progenitor cells: friend or foe in vascular disease?

Review article: endothelial progenitor cells in renal disease.

Folic acid supplementation normalizes the endothelial progenitor cell transcriptome of patients with type 1 diabetes: a case-control pilot study.

Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study.

Progenitor cells and vascular function are impaired in patients with chronic kidney disease.

Differential impact of dialysis modality on circulating endothelial progenitor cells.

Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study.

LOX-1: luring ox-LDL into the arterial wall.

Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia.

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment.

Transcriptome analysis in endothelial progenitor cell biology.

Reduced endothelial progenitor cells in children with hemodialysis but not predialysis chronic kidney disease.

The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction.

Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome.

Decreased kidney function: an unrecognized and often untreated risk factor for secondary cardiovascular events after carotid surgery.

Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis.

Hypoxia impedes vasculogenesis of in vitro engineered bone.

Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases.

Subtotal nephrectomy plus coronary ligation leads to more pronounced damage in both organs than either nephrectomy or coronary ligation.

Re: Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia.

HEALTHY BONE MARROW CELLS REDUCE PROGRESSION OF KIDNEY FAILURE BETTER THAN CKD BONE MARROW CELLS IN RATS WITH ESTABLISHED CHRONIC KIDNEY DISEASE.

ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling.

Polymer-based scaffold designs for in situ vascular tissue engineering: controlling recruitment and differentiation behavior of endothelial colony forming cells.

Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease.

Target organ cross talk in cardiorenal syndrome: animal models.

Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure.

Lgr5(+ve) stem/progenitor cells contribute to nephron formation during kidney development.

Healthy bone marrow cells reduce progression of kidney failure better than CKD bone marrow cells in rats with established chronic kidney disease.

Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients.

Autologous Bone Marrow-Derived Cell Therapy in Patients With Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Clinical Trials.

Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells.

Inaccuracy in determining mean arterial pressure with oscillometric blood pressure techniques.

Bone marrow cell therapy in hypertensive kidney disease: contribution to cardiac fibrosis?

Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus.

Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.